Your browser doesn't support javascript.
loading
Knowledge graph-based recommendation framework identifies drivers of resistance in EGFR mutant non-small cell lung cancer.
Gogleva, Anna; Polychronopoulos, Dimitris; Pfeifer, Matthias; Poroshin, Vladimir; Ughetto, Michaël; Martin, Matthew J; Thorpe, Hannah; Bornot, Aurelie; Smith, Paul D; Sidders, Ben; Dry, Jonathan R; Ahdesmäki, Miika; McDermott, Ultan; Papa, Eliseo; Bulusu, Krishna C.
Afiliação
  • Gogleva A; Biological Insight Knowledge Graph (BIKG), AI Engineering, R&D IT, AstraZeneca, Cambridge, UK.
  • Polychronopoulos D; Early Computational Oncology, Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, UK.
  • Pfeifer M; Bioscience, Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, UK.
  • Poroshin V; NLP Lab, Enterprise AI Services, IGNITE, AstraZeneca, Cambridge, UK.
  • Ughetto M; Biological Insight Knowledge Graph (BIKG), AI Engineering, R&D IT, AstraZeneca, Gothenburg, Sweden.
  • Martin MJ; Bioscience, Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, UK.
  • Thorpe H; Bioscience, Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, UK.
  • Bornot A; Data Sciences & Quantitative Biology, Discovery Sciences, R&D, AstraZeneca, Cambridge, UK.
  • Smith PD; Bioscience, Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, UK.
  • Sidders B; Early Computational Oncology, Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, UK.
  • Dry JR; Early Computational Oncology, Research and Early Development, Oncology R&D, AstraZeneca, Waltham, MA, USA.
  • Ahdesmäki M; Early Computational Oncology, Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, UK.
  • McDermott U; Bioscience, Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, UK.
  • Papa E; Biological Insight Knowledge Graph (BIKG), AI Engineering, R&D IT, AstraZeneca, Cambridge, UK. elipapa@alum.mit.edu.
  • Bulusu KC; Early Computational Oncology, Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, UK. krishna.bulusu@astrazeneca.com.
Nat Commun ; 13(1): 1667, 2022 03 29.
Article em En | MEDLINE | ID: mdl-35351890
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma Pulmonar de Células não Pequenas / Neoplasias Pulmonares Tipo de estudo: Guideline / Prognostic_studies Limite: Humans Idioma: En Revista: Nat Commun Assunto da revista: BIOLOGIA / CIENCIA Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Reino Unido
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma Pulmonar de Células não Pequenas / Neoplasias Pulmonares Tipo de estudo: Guideline / Prognostic_studies Limite: Humans Idioma: En Revista: Nat Commun Assunto da revista: BIOLOGIA / CIENCIA Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Reino Unido